Intracranial arterial calcifications as a prognostic factor for subsequent major adverse cardiovascular events (MACE)

被引：0
|
作者：
Frederik F. Strobl
Beatrice Kuhlin
Robert Stahl
Bastian O. Sabel
Andreas D. Helck
Andreas Schindler
Matthias Witt
Fabian Bamberg
Maximilian F. Reiser
Tobias Saam
机构：
[1] Ludwig-Maximilians-University Hospital Munich,Department of Radiology
[2] Ludwig-Maximilians-University Hospital Munich,Internal Medicine IV, Division of Rheumatology
[3] University Hospital Tuebingen,Department of Diagnostic and Interventional Radiology
来源：
La radiologia medica | 2018年 / 123卷
关键词：
CT; Calcification; Cardiovascular event;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：456 / 462
页数：6
相关论文
共 50 条
  • [21] Elevated lipoprotein(a) increases risk of subsequent major adverse cardiovascular events (MACE) and coronary revascularisation in incident ASCVD patients: A cohort study from the UK Biobank
    Welsh, Paul
    Al Zabiby, Anas
    Byrne, Hannah
    Benbow, Harriet R.
    Itani, Taha
    Farries, Gabriella
    Costa-Scharplatz, Madlaina
    Ferber, Philippe
    Martin, Lorraine
    Brown, Rosemary
    Fonseca, Ana Filipa
    Sattar, Naveed
    ATHEROSCLEROSIS, 2024, 389
  • [22] Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights
    Ramon Marsal, Josep
    Urreta-Barallobre, Iratxe
    Ubeda-Carrillo, Marimar
    Osorio, Dimelza
    Lumbreras, Blanca
    Lora, David
    Fernandez-Felix, Borja M.
    Oristrell, Gerard
    Rodenas-Alesina, Eduard
    Herrador, Lorena
    Ballesteros, Monica
    Zamora, Javier
    Pijoan, Jose, I
    Ribera, Aida
    Ferreira-Gonzalez, Ignacio
    TRIALS, 2022, 23 (01)
  • [23] SYSTEMATIC LITERATURE REVIEW OF UTILITY DECREMENTS ASSOCIATED WITH THE NON-FATAL MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE)
    Jindal, R.
    Natani, H.
    Gogna, S.
    Yenamandra, J.
    Laires, P. A.
    Cristino, J.
    VALUE IN HEALTH, 2018, 21 : S116 - S116
  • [24] Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights
    Josep Ramon Marsal
    Iratxe Urreta-Barallobre
    Marimar Ubeda-Carrillo
    Dimelza Osorio
    Blanca Lumbreras
    David Lora
    Borja M. Fernández-Felix
    Gerard Oristrell
    Eduard Ródenas-Alesina
    Lorena Herrador
    Mónica Ballesteros
    Javier Zamora
    Jose I. Pijoan
    Aida Ribera
    Ignacio Ferreira-González
    Trials, 23
  • [25] Acute kidney injury (AKI) outcome, a predictor of long-term major adverse cardiovascular events (MACE)
    Omotoso, Bolanle A.
    Abdel-Rahman, Emaad M.
    Xin, Wenjun
    Ma, Jennie Z.
    Scully, Kenneth W.
    Arogundade, Fatiu A.
    Balogun, Rasheed A.
    CLINICAL NEPHROLOGY, 2016, 85 (01) : 1 - 11
  • [26] A prediction model for major adverse cardiovascular events (MACE) in patients with coronavirus disease 2019 (COVID-19)
    Huang, Dong
    Yang, Huan
    Yu, He
    Wang, Ting
    Chen, Zhu
    Yao, Rong
    Liang, Zongan
    BMC PULMONARY MEDICINE, 2022, 22 (01)
  • [27] A prediction model for major adverse cardiovascular events (MACE) in patients with coronavirus disease 2019 (COVID-19)
    Dong Huang
    Huan Yang
    He Yu
    Ting Wang
    Zhu Chen
    Rong Yao
    Zongan Liang
    BMC Pulmonary Medicine, 22
  • [28] Elevated Soluble Suppressor of Tumorigenicity 2 Predict Hospital Admissions Due to Major Adverse Cardiovascular Events (MACE)
    Chen, Dongqing
    Untaru, Rossana
    Stavropoulou, Glykeria
    Assadi-Khansari, Bahador
    Kelly, Conagh
    Croft, Amanda J.
    Sugito, Stuart
    Collins, Nicholas J.
    Sverdlov, Aaron L.
    Ngo, Doan T. M.
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (08)
  • [29] Role of Copeptin as a Predictor of Major Adverse Cardiovascular Events (MACE) During Hospitalization on Acute Myocardial Infarction Patient
    Wiratama, I. P. R. S.
    Wasyanto, T.
    EUROPEAN HEART JOURNAL SUPPLEMENTS, 2021, 23 (0F)
  • [30] Can machine learning augment clinician adjudication of events in cardiovascular trials? A case study of major adverse cardiovascular events (MACE) across CVRM trials
    Lea, H.
    Hutchinson, E.
    Meeson, A.
    Nampally, S.
    Dennis, G.
    Wallander, M.
    Andersson, T.
    Persson, A.
    Johnston, S. C.
    Weatherall, J.
    Khan, F.
    Khader, S.
    EUROPEAN HEART JOURNAL, 2021, 42 : 3061 - 3061
12345